Avalo Therapeutics (AVTX) Common Equity (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Common Equity came in at $68.3 million in Q1 2026, down 44.28% YoY from $122.6 million in Q1 2025, and down 17.74% on a QoQ basis from $83.0 million in Q4 2025.
Avalo Therapeutics (AVTX) Common Equity (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Common Equity data on file, last reported at $68.3 million in Q1 2026.
- Quarterly Common Equity fell 44.28% year-over-year to $68.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.3 million (down 44.28% YoY) and the FY2025 annual result came in at $83.0 million, down 37.57% from the prior year.
- Common Equity retreated to $68.3 million in Q1 2026, from $83.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $133.0 million in Q4 2024 to a low of -$112.5 million in Q1 2024.
- A 5-year average of $29.1 million and a median of $7.3 million in 2023 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 1721.36% in 2024, down 1695.79% in 2024.
- Tracing AVTX's Common Equity over 5 years: stood at -$10.9 million in 2022, then surged by 166.92% to $7.3 million in 2023, then surged by 1721.36% to $133.0 million in 2024, then slumped by 37.57% to $83.0 million in 2025, then slipped by 17.74% to $68.3 million in 2026.
- The last three Common Equity figures came in at $68.3 million (Q1 2026), $83.0 million (Q4 2025), and $91.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | 448.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 448.66 Mn |
| Mar 31, 2026 | 68.32 Mn |
| Dec 31, 2025 | 83.05 Mn |
| Sep 30, 2025 | 91.55 Mn |
| Jun 30, 2025 | 104.57 Mn |
| Mar 31, 2025 | 122.62 Mn |
| Dec 31, 2024 | 133.03 Mn |
| Sep 30, 2024 | 21.08 Mn |
| Jun 30, 2024 | -13.61 Mn |
| Mar 31, 2024 | -112.54 Mn |
| Dec 31, 2023 | 7.30 Mn |
| Sep 30, 2023 | 14.70 Mn |
| Jun 30, 2023 | -6.97 Mn |
| Mar 31, 2023 | -6.27 Mn |
| Dec 31, 2022 | -10.92 Mn |
| Sep 30, 2022 | -2.03 Mn |
| Jun 30, 2022 | -5.95 Mn |
| Mar 31, 2022 | 6.34 Mn |
| Dec 31, 2021 | 23.08 Mn |
| Sep 30, 2021 | 40.31 Mn |